All CAR-T cell therapy articles
-
NewsScottish biotech company Lentitek secures £1m funding to advance next generation cancer treatments
Biotech company Lentitek Ltd has secured £700,000 in private funding from Equity Gap, bringing its total investment to £1 million in the last six months. It develops manufacturing technologies for lentiviral vectors, used with CAR-T cell and gene therapies.
-
NewsEngineered bacteria guide CAR-T cells to poorly infiltrated solid tumors
A new probiotic-guided chimeric antigen receptor (CAR)-T platform uses engineered bacteria to infiltrate and produce synthetic antigen targets, enabling CAR-T cells to find, identify, and destroy tumor cells in situ, according to a new study.